Advancements In Colorectal Cancer Diagnostics Market To Boost Revenues Through 2032 : Fact.MR

According to Fact.MR, a market research and competitive intelligence provider, the global colorectal cancer diagnostics market is anticipated to rise at a robust CAGR of 8.5% over the next ten years. As per this study, the market was valued at around US$ 2 Bn in 2020, and is anticipated to expand 2.2X by the end of the decade.

Incidence of colorectal cancer is increasing worldwide, and the World Health Organization (WHO) has predicted a rise of around 70% in cases by 2030. Increasing incidence of the disease can be attributed to factors such as poor lifestyle choices, unhealthy eating, aging, and diet-related disorders.

As colorectal cancer is mostly found in older adults, increasing geriatric population will also play a role in rising demand for effecting diagnostics. Increasing awareness, rising research & development on various diagnostic and treatment solutions, and introduction of effective diagnostic instruments are some of the factors that are expected to drive market expansion over the coming years.

For critical insights on this market, request for More Info - https://www.factmr.com/connectus/sample?flag=S&rep_id=70

As awareness increases in emerging and developing economies, these regions expected to see major demand for colorectal cancer diagnostics. The market in Asia Pacific is anticipated to witness the fastest growth in terms of CAGR. North America is expected to hold a dominant market share through the decade.

Key Segments Covered in Colorectal Cancer Diagnostics Industry Survey

By Test Type:
Colorectal Cancer FOB Tests
Colorectal Cancer CTC Tests
Colorectal Cancer CEA Tests
Colorectal Cancer BRAF V600 Mutation Tests
Colorectal Cancer Immunohistochemistry Tests
C-kit/CD117
KRAS Mutation Tests
Others

By End User:
Hospital-associated Labs
Independent Diagnostic Laboratories
Cancer Research Institutes
Others

Request more information about Report Methodology - https://www.factmr.com/connectus/sample?flag=RM&rep_id=70

Key Takeaways from Market Study

By 2031 the global colorectal cancer diagnostics market is anticipated to attain an estimate net worth of US$ 4.5 Bn.
Over the next ten years, the market is predicted to rise at a high CAGR of 8.5%.
North America is anticipated to hold a dominant market share.
Emerging economies are expected to see major rise in demand for effective colorectal cancer diagnostics.
Increasing research & development, rising disease awareness, and aging population are major factors anticipated to influence demand for colorectal cancer diagnostics.

Competitive Landscape

Some of the key players providing colorectal
cancer diagnostic systems are Danaher Corporation, Rosetta Genomics, Epigenomics AG, Exact Science Corporation, Pathway Genomics Corporation, Biocept Inc., Cancer Genetics Inc, and Foundation Medicine Inc.

In October 2021, Lirio announced the launch of a brand new Precision Nudging solution that would stimulate people to schedule and attend colorectal cancer screenings with their healthcare providers. The first provider to employ this for its patients was Rochester Regional Health (RRH) in New York.

Count Me In, a nonprofit cancer research initiative, announced a new initiative by the name of The Colorectal Cancer Project, which is inviting people across the U.S. who have been diagnosed with the disease in their lifetime. The objective is to gain a better understanding of the disease and find the cause of its rising incidence in the younger population, which is not considered very common.

For in-depth competitive analysis, Now - https://www.factmr.com/checkout/70

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email : sales@factmr.com
Website : https://www.factmr.com

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range - from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we'll be an able research partner.

This release was published on openPR.